Andrew Acheson, co-manager of the €1.4bn Pioneer SICAV - US Fundamental Growth fund, said he defended himself against August's biotech sell-off by holding established stocks with room for growth rather than "paying for the hope of the future".
The manager said the fund outperformed its Russell 1000 Growth benchmark over the last three months, despite being overweight the wider healthcare sector during a period when the NASDAQ Biotechnology index...
New transparency rules to be introduced
Co-managers of £5.5bn AUM Artemis Income fund
Round-up of diversity coverage
Industry Voice: Sponsored by Neptune
Latest news and analysis